시간 외 거래: 18.85 0.04 +0.21%

Jasper Therapeutics Inc (JSPR)

Jasper Therapeutics Inc 주식(JSPR)의 최신 뉴스

Jasper Therapeutics Inc (JSPR)

Jasper Therapeutics Inc 주식(JSPR)의 최신 뉴스

Jasper Therapeutics' SWOT analysis: briquilimab's potential in mast cell diseases - Investing.com

Fanconi Anemia Market Expected to Experience Major Growth - openPR

Fanconi Anemia Market Expected to Experience Major Growth by 2034, According to DelveInsight | Novartis, Foresee Pharma, Rocket Pharma, Jasper Therapeutics - The Globe and Mail

Jasper Therapeutics (NASDAQ:JSPR) Earns "Market Outperform" Rating from JMP Securities - MarketBeat

Jasper Therapeutics Inc [JSPR] Shares Jump Approximately 156.76% Over the Year - Knox Daily

Insider Selling: Kabot Brian, Momentus Inc [MNTS] Director divested 400 shares - Knox Daily

Jasper Therapeutics Inc (JSPR) Stock: Uncovering 52-Week Market Trends - The InvestChronicle

Jasper Therapeutics Inc’s Market Journey: Closing Weak at 18.23, Down -16.34 - The Dwinnex

Jasper concerns driven by Celldex data ‘overdone,’ says Stifel - TipRanks

Front Street Capital Management Inc. Sells 4,073 Shares of Kimball Electronics, Inc. (NASDAQ:KE) - Defense World

First Light Asset Management LLC Sells 482 Shares of Simulations Plus, Inc. (NASDAQ:SLP) - Defense World

Booz Allen Hamilton Holding Co. (NYSE:BAH) Shares Acquired by Providence Capital Advisors LLC - Defense World

Needham maintains Buy rating on Jamf shares with no price target change - Investing.com India

When (JSPR) Moves Investors should Listen - Stock Traders Daily

Y-mAbs Therapeutics (NASDAQ:YMAB) Trading Down 4.7% - Defense World

Jasper Therapeutics, Inc. (NASDAQ:JSPR) Shares Sold by Ally Bridge Group NY LLC - Defense World

Jasper is open to visitors again — but what can tourists expect? - CBC.ca

Jasper Therapeutics, Inc. (NASDAQ:JSPR) Receives Average Rating of "Buy" from Brokerages - MarketBeat

Massachusetts Financial Services Co. MA Decreases Stock Position in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) - Defense World

Ally Bridge Group NY LLC Trims Stock Holdings in Jasper Therapeutics, Inc. (NASDAQ:JSPR) - MarketBeat

Quest Partners LLC Has $40,000 Position in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) - Defense World

"Let’s go crazy in front of the best fans": Kentucky's Jasper Johnson tries to lure Caleb Wilson and Acaden Lewis to the Wildcats - Sportskeeda

Jasper Johnson pitches Kentucky to Caleb Wilson and Acaden Lewis - KSR

Short Interest in Jasper Therapeutics, Inc. (NASDAQ:JSPR) Increases By 8.7% - Defense World

Jasper Therapeutics, Inc. (NASDAQ:JSPR) Sees Large Increase in Short Interest - MarketBeat

Sources Say goes LIVE with Kentucky commit Jasper Johnson! - KSR

Aquestive Therapeutics Inc’s latest rating changes from various analysts - Knox Daily

Jewett-Cameron Adds Three New Supply Partners for its Products - NRToday.com

Jasper Johnson had a month of being "torn" before committing to Kentucky - A Sea Of Blue

Jasper lifting state of local emergency, receives 13 EOIs for interim housing - Hamilton Spectator

Quest Partners LLC Purchases 982 Shares of Axon Enterprise, Inc. (NASDAQ:AXON) - Defense World

Financial Analysis: ADMA Biologics (NASDAQ:ADMA) vs. Jasper Therapeutics (NASDAQ:JSPR) - Defense World

Jasper state of local emergency ending; visitors asked to be respectful - CTV News Edmonton

Jasper ending state of emergency as focus shifts to long-term recovery from wildfire - Winnipeg Free Press

Jasper Therapeutics COO sells shares worth over $19,000 By Investing.com - Investing.com Australia

(JSPR) Trading Report - Stock Traders Daily

Jasper Therapeutics COO sells shares worth over $19,000 - Investing.com

Jasper Therapeutics, Inc. (NASDAQ:JSPR) COO Sells $19,107.00 in Stock - MarketBeat

Jasper Therapeutics gets Canada nod for asthma study - Investing.com

Jasper Therapeutics Announces Health Canada Clearance of - GlobeNewswire

Jasper Therapeutics Announces Health Canada Clearance of Clinical Trial Application for Phase 1b/2a Study of Briquilimab in Asthma - StockTitan

Jasper Therapeutics (NASDAQ:JSPR) Receives Overweight Rating from Cantor Fitzgerald - Defense World

Jasper Therapeutics (NASDAQ:JSPR) Receives New Coverage from Analysts at JMP Securities - Defense World

Cantor Fitzgerald Reaffirms "Overweight" Rating for Jasper Therapeutics (NASDAQ:JSPR) - MarketBeat

Jasper Therapeutics stock set for growth with novel stem cell therapyJMP - Investing.com Canada

JMP Securities Begins Coverage on Jasper Therapeutics (NASDAQ:JSPR) - MarketBeat

Jasper Therapeutics initiated with an Outperform at JMP Securities - TipRanks

Addiction Therapeutics Market Current Impact to Make Big Changes - La Funcion mx

Jasper Therapeutics to Present at Present at Upcoming September Investor Conferences - GlobeNewswire

Jasper Therapeutics to Present at Present at Upcoming September Investor Conferences - Yahoo Finance UK

Jasper Therapeutics to Present at Present at Upcoming September Investor Conferences - Yahoo Finance

Jasper Therapeutics to Present at Present at Upcoming September Investor Conferences - StockTitan

We're Keeping An Eye On Jasper Therapeutics' (NASDAQ:JSPR) Cash Burn Rate - Simply Wall St

Analysts Set Jasper Therapeutics, Inc. (NASDAQ:JSPR) Price Target at $73.43 - MarketBeat

Objective long/short (JSPR) Report - Stock Traders Daily

Jasper Therapeutics (NASDAQ:JSPR) Receives “Outperform” Rating from Evercore ISI - Defense World

Jasper Therapeutics (NASDAQ:JSPR) Rating Reiterated by Evercore ISI - MarketBeat

Jasper Therapeutics, Inc. Expected to Earn FY2024 Earnings of ($3.98) Per Share (NASDAQ:JSPR) - MarketBeat

MediciNova (NASDAQ:MNOV) Coverage Initiated by Analysts at StockNews.com - Defense World

FY2024 Earnings Forecast for Immatics (NASDAQ:IMTX) Issued By Cantor Fitzgerald - Defense World

Brokers Issue Forecasts for NICE Ltd.’s FY2024 Earnings (NASDAQ:NICE) - Defense World

Short Interest in Jasper Therapeutics, Inc. (NASDAQ:JSPR) Grows By 40.2% - Defense World

Eagle Pharmaceuticals (NASDAQ:EGRX) Research Coverage Started at StockNews.com - Defense World

Jasper Therapeutics, Inc. (NASDAQ:JSPR) Forecasted to Post Q3 2024 Earnings of ($1.02) Per Share - MarketBeat

Capital One Financial Analysts Raise Earnings Estimates for Jasper Therapeutics, Inc. (NASDAQ:JSPR) - Defense World

HC Wainwright Comments on Jasper Therapeutics, Inc.’s Q3 2024 Earnings (NASDAQ:JSPR) - Defense World

Q3 2024 Earnings Forecast for Jushi Holdings Inc. Issued By Seaport Res Ptn (OTCMKTS:JUSHF) - Defense World

Jasper Therapeutics (NASDAQ:JSPR) PT Lowered to $68.00 - Defense World

JSPR과 유사한 종목